Keybanc analyst John Vinh maintains Marvell Technology (NASDAQ:MRVL) with a Overweight and raises the price target from $65 to $70.
Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?
The FDA has signed off Bio-Path Holdings Inc’s (NASDAQ:BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia…